INVO Fertility, Inc. (IVF): M&A transaction — INVO Fertility divests majority holdings in NTI, retains preferred stake and note

INVO Fertility, Inc.

Effective June 2, 2025, INVO redeemed all Series C-1 Preferred for 3,227,813 shares of NTI Class A Common, ceasing to hold NTI common.
INVO retains 6,300 shares of NTI Series A Preferred, representing 19.9% on an as-converted basis, and a $4.8M secured convertible note from NTI.
Pro forma net loss improves: Q1 2025 from $17.4M to $16.2M; FY 2024 from $9.1M to $5.7M after removing NTI operations.
The divestiture removes NTI's intangible assets ($14.8M) and goodwill ($3.0M) from INVO's balance sheet.

item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

INVO Fertility, Inc. completed a disposition (closed 2025-06-02).

Action: disposition
Closing: 2025-06-02

Exact text from the filing

Effective June 2, 2025, INVO Fertility, Inc., a Nevada corporation (the “ Company ”) consummated the divestiture of a majority of its holdings in NAYA Therapeutics Inc., a Delaware Corporation (“ NTI ”).

View on SEC.gov

30 m&a transactions filed in the last 30 days. Browse all m&a transactions →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-014019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.